Marex Group plc announces investment in Ruminant Biotech

Marex Group plc (‘Marex’ or the ‘Group’; NASDAQ: MRX), the diversified global financial services platform, today announces that it will take a minority stake in Ruminant Biotech (“RBT”), a New Zealand-based business that has developed technology to reduce methane emissions from pasture-based livestock.

RBT will use the funds to advance its development of the technology, which trials have indicated can reduce methane production in animals treated with a single dose of the product for a period of 100 days. These funds will also help progress regulatory approvals in priority markets globally. The reduction in methane as a result of the use of this technology can be quantified and converted into carbon credits, creating a pathway into the growing carbon market.

Marex’s investment in RBT aligns with its strategy to grow its environmental business and allows it to access to a new stream of carbon credits and potentially tap into a wider carbon client base. It also creates an opportunity for Marex to further diversify its emissions reduction offering, leaving it well placed to support its clients as they transition to a low carbon economy.

As part of its investment, it has also been agreed that Marex will act as exclusive broker and market maker in respect of a number of RBT’s own carbon credits generated by the project.